
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c)
AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No.)***

ASLAN Pharmaceuticals Limited

(Name of Issuer)

**Ordinary shares, par value NT\$10.00 per share (“Shares”), represented by American
Depositary Shares (“ADSs”)
(one ADS represents five Shares)
(Title of Class of Securities)**

04522R101**
(CUSIP Number)

May 8, 2018
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

** CUSIP number of the ADSs, each of which represents five Shares.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAMES OF REPORTING PERSONS Temasek Holdings (Private) Limited	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Singapore	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 8,390,375 Shares
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 8,390,375 Shares
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 8,390,375 Shares	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.2%*	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC	

* Based on 160,248,940 Shares outstanding as of June 17, 2019, as set forth in the Issuer's registration statement on Form F-1 filed with the Securities and Exchange Commission (the "Commission") on such date.

Item 1(a). Name of Issuer:

ASLAN Pharmaceuticals Limited (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

83 Clemenceau Avenue #12-03 UE Square
Singapore 239920

Item 2(a). Name of Person Filing:

Temasek Holdings (Private) Limited ("Temasek")

Item 2(b). Address of Principal Business Office or, if none, Residence:

60B Orchard Road, #06-18 Tower 2, The Atrium@Orchard, Singapore 238891

Item 2(c). Citizenship:

Republic of Singapore

Item 2(d). Title of Class of Securities:

Ordinary shares, par value NT\$10.00 per Share, represented by ADSs (one ADS represents five Shares. References to "NT\$" are to New Taiwan dollars, the legal currency of the Republic of China.

Item 2(e). CUSIP Number:

04522R101 (CUSIP number of the Issuer's ADSs, each of which represents five Shares)

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4. Ownership.**(a) Amount beneficially owned:**

As of the date hereof, V-Sciences Investments Pte Ltd ("V-Sciences") directly owns in aggregate 7,112,375 Shares (in the form of 1,422,475 ADSs each representing five Shares) and Aranda Investments Pte. Ltd. ("Aranda") directly owns in aggregate 1,278,000 Shares.

V-Sciences is a wholly-owned subsidiary of Temasek Life Sciences Private Limited ("TLS"), which in turn is a wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a wholly-owned subsidiary of Temasek. Aranda is a wholly-owned subsidiary of Seletar Investments Pte Ltd ("Seletar"), which in turn is a wholly-owned subsidiary of Temasek Capital (Private) Limited ("Temasek Capital"), which in turn is a wholly-owned subsidiary of Temasek.

Each of TLS and FMPL, through the ownership described herein, may be deemed to beneficially own the Shares directly owned by V-Sciences, and each of Seletar and Temasek Capital, through the ownership described herein, may be deemed to beneficially own the Shares directly owned by Aranda. Accordingly, Temasek, through the ownership described herein, may be deemed to beneficially own the aggregate 8,390,375 Shares beneficially owned by FMPL and Temasek Capital in aggregate.

(b) Percent of class:

As of the date hereof, the 8,390,375 Shares deemed to be beneficially owned by Temasek as described above represents approximately 5.2% of the Shares outstanding. This is based on 160,248,940 Shares outstanding as of June 17, 2019, as set forth in the Issuer's registration statement on Form F-1 filed with the Commission on such date.

(c) Number of shares as to which the person has:

With respect to the shared power to vote, or to direct the vote, and to dispose, or to direct the disposition of, the Shares, please see Item 4(a) above regarding qualifications as to beneficial ownership.

- (i) Sole power to vote or to direct the vote:
0.
- (ii) Shared power to vote or to direct the vote:
8,390,375 Shares.
- (iii) Sole power to dispose or to direct the disposition of:
0.
- (iv) Shared power to dispose or to direct the disposition of:
8,390,375 Shares.

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 5, 2019

TEMASEK HOLDINGS (PRIVATE) LIMITED

By: /s/ Andrew Ang Lye Whatt

Name: Andrew Ang Lye Whatt

Title: Authorized Signatory